Should multiple sclerosis be only treated by experts?

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects more than 2.5 million patients worldwide. Dysregulation of the immune system is thought to be involved in MS, although the exact cause and pathogenesis remain elusive. While curative therapy is yet to be provided, more than ten disease-modifying drugs (DMD), mostly targeting the immune system, have been developed. Six DMDs are currently available in Japan. The modes of action are not completely understood for most DMDs. Thus, optimization of DMD treatment, according to the underlying pathology, is no easy task. MS experts select the most ideal DMD by balancing the drug efficacy and the risk, and may consider switching to other DMDs when the effect is suboptimal. The systemization of these processes is difficult. Knowing this, should MS be only treated by experts?.

Original languageEnglish
Pages (from-to)17-25
Number of pages9
JournalNeuro-Ophthalmology Japan
Volume35
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Multiple Sclerosis
Immune System
Pharmaceutical Preparations
Demyelinating Diseases
Drug Delivery Systems
Japan
Central Nervous System
Pathology
Therapeutics

Keywords

  • Disease-modifying drugs
  • Multiple sclerosis
  • Optimization
  • Progressive multifocal leukoencephalopathy
  • Risk-benefit profile

ASJC Scopus subject areas

  • Ophthalmology
  • Clinical Neurology

Cite this

Should multiple sclerosis be only treated by experts? / Nakahara, Jin.

In: Neuro-Ophthalmology Japan, Vol. 35, No. 1, 01.01.2018, p. 17-25.

Research output: Contribution to journalArticle

@article{f96e64007994492e8950596c3363e44e,
title = "Should multiple sclerosis be only treated by experts?",
abstract = "Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects more than 2.5 million patients worldwide. Dysregulation of the immune system is thought to be involved in MS, although the exact cause and pathogenesis remain elusive. While curative therapy is yet to be provided, more than ten disease-modifying drugs (DMD), mostly targeting the immune system, have been developed. Six DMDs are currently available in Japan. The modes of action are not completely understood for most DMDs. Thus, optimization of DMD treatment, according to the underlying pathology, is no easy task. MS experts select the most ideal DMD by balancing the drug efficacy and the risk, and may consider switching to other DMDs when the effect is suboptimal. The systemization of these processes is difficult. Knowing this, should MS be only treated by experts?.",
keywords = "Disease-modifying drugs, Multiple sclerosis, Optimization, Progressive multifocal leukoencephalopathy, Risk-benefit profile",
author = "Jin Nakahara",
year = "2018",
month = "1",
day = "1",
doi = "10.11476/shinkeiganka.35.17",
language = "English",
volume = "35",
pages = "17--25",
journal = "Neuro-Ophthalmology Japan",
issn = "0289-7024",
publisher = "Neuro-Ophthalmology Society of Japan",
number = "1",

}

TY - JOUR

T1 - Should multiple sclerosis be only treated by experts?

AU - Nakahara, Jin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects more than 2.5 million patients worldwide. Dysregulation of the immune system is thought to be involved in MS, although the exact cause and pathogenesis remain elusive. While curative therapy is yet to be provided, more than ten disease-modifying drugs (DMD), mostly targeting the immune system, have been developed. Six DMDs are currently available in Japan. The modes of action are not completely understood for most DMDs. Thus, optimization of DMD treatment, according to the underlying pathology, is no easy task. MS experts select the most ideal DMD by balancing the drug efficacy and the risk, and may consider switching to other DMDs when the effect is suboptimal. The systemization of these processes is difficult. Knowing this, should MS be only treated by experts?.

AB - Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects more than 2.5 million patients worldwide. Dysregulation of the immune system is thought to be involved in MS, although the exact cause and pathogenesis remain elusive. While curative therapy is yet to be provided, more than ten disease-modifying drugs (DMD), mostly targeting the immune system, have been developed. Six DMDs are currently available in Japan. The modes of action are not completely understood for most DMDs. Thus, optimization of DMD treatment, according to the underlying pathology, is no easy task. MS experts select the most ideal DMD by balancing the drug efficacy and the risk, and may consider switching to other DMDs when the effect is suboptimal. The systemization of these processes is difficult. Knowing this, should MS be only treated by experts?.

KW - Disease-modifying drugs

KW - Multiple sclerosis

KW - Optimization

KW - Progressive multifocal leukoencephalopathy

KW - Risk-benefit profile

UR - http://www.scopus.com/inward/record.url?scp=85044997555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044997555&partnerID=8YFLogxK

U2 - 10.11476/shinkeiganka.35.17

DO - 10.11476/shinkeiganka.35.17

M3 - Article

AN - SCOPUS:85044997555

VL - 35

SP - 17

EP - 25

JO - Neuro-Ophthalmology Japan

JF - Neuro-Ophthalmology Japan

SN - 0289-7024

IS - 1

ER -